BPMX - BioPharmX Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
0.21270
+0.00170 (+0.80569%)
As of 10:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.21100
Open0.21990
Bid0.21590 x 4800
Ask0.21600 x 9400
Day's Range0.21010 - 0.21990
52 Week Range0.10000 - 0.89700
Volume996,279
Avg. Volume14,651,043
Market Cap40.413M
Beta-0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.25800
Earnings DateMar 21, 2018 - Mar 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.05
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Today’s Research Reports on Trending Tickers: BioPharmX and MediWound

    NEW YORK, NY / ACCESSWIRE / March 21, 2018 / Stock markets rallied Tuesday on gains from the energy and consumer discretionary sector. Wall Street appears to be eagerly awaiting details from the Federal ...

  • PR Newswirelast month

    BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather

    MENLO PARK, Calif. , March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it has cancelled ...

  • PR Newswirelast month

    U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions

    MENLO PARK, Calif., March 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the U.S. Patent and Trademark Office has granted the first in what the company expects will be a new family of patents protecting its novel topical gel delivery system that allows for greater bioavailability of an active pharmaceutical ingredient (API) . The patent (U.S. Patent No. 9,918,998), entitled "Pharmaceutical Tetracycline Composition For Dermatological Use," covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. This is the fourth U.S. patent issuance BioPharmX has received.

  • PR Newswirelast month

    BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference

    MENLO PARK, Calif. , March 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present ...

  • Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven
    Simply Wall St.2 months ago

    Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven

    BioPharmX Corporation’s (AMEX:BPMX): BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women’s health markets. The US$37.11M market-cap posted aRead More...

  • PR Newswire2 months ago

    BioPharmX to Present at 30th Annual ROTH Conference

    MENLO PARK, Calif. , March 5, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announces that it will present ...

  • GlobeNewswire3 months ago

    Investor Expectations to Drive Momentum within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX — Discovering Underlying Factors of Influence

    NEW YORK, Feb. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic ...

  • PR Newswire3 months ago

    BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin

    MENLO PARK, Calif., Jan. 26, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing dermatology products, today announced that a revolutionary technique to measure how effectively a single dose of topically applied minocycline reached the epidermis and pilosebaceous unit of human facial skin may potentially explain early onset of efficacy observed in two investigational BioPharmX drugs. The measurement was accomplished using fluorescence lifetime imaging microscopy (FLIM) to visualize the delivery of BPX-011 for acne and BPX-041 for rosacea. The specificity and sensitivity of the technique enabled researchers to begin quantifying the local distribution of minocycline in a given layer of skin.

  • PR Newswire3 months ago

    BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month

    MENLO PARK, Calif., Jan. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will present to the medical community preliminary data from the treatment of rosacea using its novel topical gel, BPX-04. BPX-04 is the company's latest addition to its clinical pipeline.  It is the second product built on the proprietary, patent-pending BioPharmX hydrophilic topical delivery system.

  • ACCESSWIRE4 months ago

    Free Post Earnings Research Report: BioPharmX’s Adjusted EPS Beat Expectations

    LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free earnings report on BioPharmX Corp. (NYSE: BPMX ). If you want access to this report all you need to do is sign ...

  • How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?
    Simply Wall St.4 months ago

    How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead?

    The most recent earnings announcement BioPharmX Corporation’s (AMEX:BPMX) released in October 2017 showed that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...

  • How BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance
    Simply Wall St.4 months ago

    How BioPharmX Corporation’s (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance

    Examining how BioPharmX Corporation (AMEX:BPMX) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense check toRead More...

  • ACCESSWIRE4 months ago

    Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075

    Stock Monitor: BioPharmX Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX ) ("MabVax"), ...

  • BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017
    Capital Cube4 months ago

    BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017

    Categories: Yahoo FinanceGet free summary analysis BioPharmX Corp. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of BioPharmX Corp. – Supernus Pharmaceuticals, Inc., Foamix Pharmaceuticals Ltd., Achaogen, Inc. and Zogenix, Inc. (SUPN-US, FOMX-US, AKAO-US and ZGNX-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • PR Newswire5 months ago

    BioPharmX Reports Third Quarter 2018 Financial Results

    MENLO PARK, Calif. , Dec. 7, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focusing on dermatology, today announces its financial results for the ...

  • PR Newswire5 months ago

    BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017

    MENLO PARK, Calif., Dec. 4, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may exhibit relevant antimicrobial and anti-inflammatory properties for the treatment of acne. Data from cellular analysis shows minocycline's effectiveness may be due to its antimicrobial effect and its ability to modulate the effects of pro-inflammatory cytokines associated with acne pathology.

  • PR Newswire5 months ago

    BioPharmX Corporation Announces Pricing of Public Offering

    MENLO PARK, Calif. , Nov. 21, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE AMERICAN: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the pricing ...

  • Should You Be Concerned About BioPharmX Corporation’s (BPMX) Shareholders?
    Simply Wall St.5 months ago

    Should You Be Concerned About BioPharmX Corporation’s (BPMX) Shareholders?

    In this analysis, my focus will be on developing a perspective on BioPharmX Corporation’s (AMEX:BPMX) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • PR Newswire6 months ago

    BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans

    MENLO PARK, Calif., Nov. 8, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding design of its planned phase 3 clinical trial for BPX-011, the company's topical minocycline gel for the treatment of inflammatory lesions of acne vulgaris. The company has incorporated feedback from the FDA on key elements of its phase 3 acne program and received clear guidance regarding expectations and requirements for clinical, non-clinical, and chemistry, manufacturing and controls (CMC) needed to support a post phase 3 NDA submission.

  • Capital Cube6 months ago

    ETFs with exposure to BioPharmX Corp. : November 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioPharmX Corp. Here are 5 ETFs with the largest exposure to BPMX-US. Comparing the performance and risk of BioPharmX Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire6 months ago

    BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017

    MENLO PARK, Calif., Oct. 18, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) will share research suggesting that BPX-01, the company's topical gel formulation of minocycline, may be useful in the treatment of inflammatory skin diseases, including acne and papulopustular rosacea, particularly as the medical community has growing concerns about antibiotic resistance secondary to systemic exposure. A presentation at the Re-entering Antibacterial Discovery and Development Summit on Oct. 18-20 in Boston concludes that minocycline is effective in fighting gram-positive and gram-negative bacteria, as well as other micro-organisms implicated in rosacea and acne – while also alleviating the inflammation they cause.

  • PR Newswire6 months ago

    BioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery

    MENLO PARK, Calif., Oct. 11, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) researchers were part of a national scientific team that developed an innovative way to use nonlinear optical imaging to confirm the efficiency and quantity of the delivery of new drugs. A presentation at the 2017 Fall Clinical Dermatology Conference will show how researchers from BioPharmX and the Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School used a suite of imaging techniques in what is called "Pharmacokinetic Tomography" to confirm highly localized delivery of BPX-01, BioPharmX's unique topical, hydrophilic gel formulation of minocycline for the treatment of acne vulgaris, to the area of the skin where acne develops.